Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Evan C. Chen, Jorge Ramos, R. Coleman Lindsley, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2023-172763

Published: 2023

Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2023) 142 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2023-173283

Published: 2023

Journal Articles

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

Shai Shimony, Jacqueline S. Garcia, Julia Keating, Evan C. Chen, Marlise R. Luskin, Maximilian Stahl, Donna S. Neuberg, Daniel J. DeAngelo, Richard M Stone, R. Coleman Lindsley

Blood (2023) 142 (Supplement 1): 977.

https://doi.org/10.1182/blood-2023-173935

Published: 2023

Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2023-174285

Published: 2023

Journal Articles

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Eric S. Winer, Jacqueline S. Garcia, Richard M Stone, Martha Wadleigh, Marlise R. Luskin, Maximilian Stahl, Evan C. Chen, Rebecca Leonard, Alexis Noyes, Ilene Galinsky, Rashmi Deshpande, Pascal Borderies, Vincent O'Neill, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2023-186598

Published: 2023

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Blood (2023) 142 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2023-174790

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 424.

https://doi.org/10.1182/blood-2023-186822

Published: 2023

Journal Articles

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood (2023) 142 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2023-174283

Published: 2023

Journal Articles

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Blood (2023) 142 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2023-185220

Published: 2023

Journal Articles

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2023-186376

Published: 2023

Journal Articles

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3- wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Shai Shimony, Geoffrey G Fell, Evan C. Chen, Harrison Tsai, Martha Wadleigh, Eric S. Winer, Jacqueline S. Garcia, Marlise R. Luskin, Maximilian F. Stahl, Donna S. Neuberg, Daniel J DeAngelo, R. Coleman Lindsley, Richard M. Stone

Blood (2022) 140 (Supplement 1): 8938–8939.

https://doi.org/10.1182/blood-2022-162716

Published: 2022

Journal Articles

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Blood (2022) 140 (Supplement 1): 11026–11028.

https://doi.org/10.1182/blood-2022-159615

Published: 2022

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Anand Ashwin Patel, James J. Yoon, Hannah Johnston, Evan C. Chen, Madelyn Burkart, Timothy Seijung Oh, Sunil G. Iyer, Ellen Madarang, Iyana Gross, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Rory Michael Shallis, Guru Subramanian Guru Murthy, Vikas Gupta, Kristen M. Pettit, John Cursio, Olatoyosi Odenike

Blood (2022) 140 (Supplement 1): 6860–6862.

https://doi.org/10.1182/blood-2022-157603

Published: 2022

Journal Articles

Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax

Evan C. Chen, Yiwen Liu, Eric S. Winer, Marlise R. Luskin, Martha Wadleigh, Andrew A. Lane, Rahul S. Vedula, Coleman Lindsley, Kevin Copson, Anne Charles, Donna S. Neuberg, Nicolas C. Issa, Daniel J. DeAngelo, Richard M. Stone, Jacqueline S. Garcia

Blood (2021) 138 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2021-148717

Published: 2021

Journal Articles

Outcomes of IDH1 - and IDH2 -Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Evan C. Chen, MD, Shuli Li, PhD, Ann-Kathrin Eisfeld, MD, Marlise R Luskin, MDMS, Alice S. Mims, MD, Daniel Jones, MD PhD, Joseph H. Antin, MD, Corey Cutler, MD MPH, FRCPC, John Koreth, MBBS, DPhil, Vincent T. Ho, MD, Mahasweta Gooptu, MD, Rizwan Romee, MD, Areej El-Jawahri, MD, Steven L. McAfee, MD, Zachariah Defilipp, MD, Robert J. Soiffer, MD, Yi-Bin Chen, MD, Amir T. Fathi

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140353

Published: 2020

Journal Articles

Treatment of Acquired Hemophilia a with Rituximab and Emicizumab

Evan C. Chen, MD, William J. Gibson, MD PhD, Paula Temoczko, NP, Nathan T. Connell, MDMPH, Robert Handin, MD, Aric D. Parnes, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137262

Published: 2020

Journal Articles

Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations

Evan C. Chen, MD, Gabriela S. Hobbs, MD, Philip C. Amrein, MD, Timothy A. Graubert, MD, Amir T. Fathi, MD, Andrew M. Brunner, MD

Blood (2018) 132 (Supplement 1): 4364.

https://doi.org/10.1182/blood-2018-99-111982

Published: 2018

Journal Articles

Increased Incidence of Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia Among Adults of Hispanic Ethnicity: A Population Based Study

Ashley M. Perry, BS, Evan C. Chen, MD, Marla M. Jalbut, MD, Lillian Werner, MS, Gabriela S. Hobbs, MD, Philip C. Amrein, MD, Amir T. Fathi, MD MD BS, Andrew M. Brunner, MD

Blood (2017) 130 (Supplement 1): 2570.

https://doi.org/10.1182/blood.V130.Suppl_1.2570.2570

Published: 2017

Journal Articles

The Impact of Antimicrobial Prophylaxis during Induction Chemotherapy for Acute Myeloid Leukemia in the Current Era

Marla M. Jalbut, MD, Evan C. Chen, MD, Gabriela S. Hobbs, MD, Ashley M. Perry, BS, Lillian Werner, MS, Philip C. Amrein, MD, Amir T. Fathi, MD MD BS, Andrew M. Brunner, MD

Blood (2017) 130 (Supplement 1): 2586.

https://doi.org/10.1182/blood.V130.Suppl_1.2586.2586

Published: 2017

NARROW

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3- wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax

Outcomes of IDH1 - and IDH2 -Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Treatment of Acquired Hemophilia a with Rituximab and Emicizumab

Clinical Outcomes Following Frontline Chemotherapy for Patients with Myeloid Malignancies Harboring Splicing Factor Mutations

Increased Incidence of Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia Among Adults of Hispanic Ethnicity: A Population Based Study

The Impact of Antimicrobial Prophylaxis during Induction Chemotherapy for Acute Myeloid Leukemia in the Current Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only